CRB Monitor Securities Database Updates
During the week of July 31 - August 6, 2023, CRB Monitor’s research team made several updates to securities’ information and added source documents & relevant news articles to the CRB Monitor database.
Summary of the updates for the Week of July 31 - August 6, 2023:
|
Tier |
Total # |
Active / Inactive / Pre-IPO |
Added |
Removed |
Net Change |
|
Tier 1A |
147 |
123 / 22 / 2 |
+0 | -0 | +0 |
|
Tier 1B |
728 |
574 / 152 / 2 |
+0 | -0 | +0 |
|
Tier 2 |
341 |
316 / 20 / 5 |
+1 | -0 | +1 |
|
Tier 3 |
502 |
474 / 27 / 1 |
+0 | -0 | +0 |
|
Total Issuances |
1,718 |
1,487 / 221 / 10 |
+1 | -0 | +1 |
|
Total Issuers (w/o Pre-IPOs) |
1,292 |
- |
+1 | -0 | +1 |
|
Total Issuers (w/ Pre-IPOs) |
1,302 |
- |
+1 | -0 | +1 |
- Added 1 Tier 2 Security:
- +1 = New CRB: ("Bioxyne Limited")
- +1 = New CRB: ("Bioxyne Limited")
All newly-identified CRBs during the week:
|
Company Name |
Tier |
Pure-Play | Sector |
Description |
|
(ASX: BXN) |
2 | Yes | CBD - Pharma & Biotech | Bioxyne Limited is an international life sciences and novel medicines development company with operations in Australia (head office), United Kingdom, Japan, Malaysia, Switzerland, Czechia, France and the United States serving customers world-wide. The company's key activity is healthcare which includes the development and sale of over- the-counter healthcare products, such as its patented probiotic strain PCC and its CBD (novel foods, FSA) and nootropic supplements. Its pre-pharma development pipeline of health and wellness products allow it to bring new products to market quickly and reach commercial scale and profitability while generating observational data and customer feedback on efficacy. |